

**paracetamol 500mg/50ml intravenous infusion (Perfalgan)  
(No. 172/05)**

---

**Bristol Myers Squibb**  
Product Update

**8 April 2005**

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

Paracetamol 500mg/50ml intravenous infusion (Perfalgan<sup>®</sup>) is accepted for use in children weighing less than 33 kg but more than 10kg for the short-term treatment of moderate pain following surgery, and short-term treatment of fever, when administration by the intravenous route is clinically justified.

This updates SMC advice No. 137/04 which covered other patient groups.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including Wednesday, 9 February 2005.*

**Vice Chairman**  
**Scottish Medicines Consortium**